Role of the ubiquitin proteasome system in Parkinson's disease

Parkinson's disease (PD) is the most common neurodegenerative movement disorder. Although a subject of intense research, the etiology of PD remains poorly understood. Recently, several lines of evidence have implicated an intimate link between aberrations in the ubiquitin proteasome system (UPS) and PD pathogenesis. Derangements of the UPS, which normally functions as a type of protein degradation machinery, lead to alterations in protein homeostasis that could conceivably promote the toxic accumulation of proteins detrimental to neuronal survival. Not surprisingly, various cellular and animal models of PD that are based on direct disruption of UPS function reproduce the most prominent features of PD. Although persuasive, new developments in the past few years have in fact raised serious questions about the link between the UPS and PD. Here I review current thoughts and controversies about their relationship and discuss whether strategies aimed at mitigating UPS dysfunction could represent rational ways to intervene in the disease.Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

• Publication year

  2007

• Venue

  BMC Biochemistry

• Publication date

  2007-11-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/1471-2091-8-S1-S13PMID 18047737PMCID 2106364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuronal specificity of α-synuclein toxicity and effect of Parkin co-expression in primates

  2007cited by this paper
• Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and α-Synuclein*

  2007cited by this paper
• DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice.

  2007cited by this paper
• Proteasome-Independent Functions of Ubiquitin in Endocytosis and Signaling

  2007cited by this paper
• Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates.

  2007cited by this paper
• DJ-1 and Parkin Modulate Dopamine-dependent Behavior and Inhibit MPTP-induced Nigral Dopamine Neuron Loss in Mice.

  2007influential reference
• Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle

  2007cited by this paper
• Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030

  2007cited by this paper
• Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity.

  2006cited by this paper
• Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications.

  2006cited by this paper
• Proteasome dysfunction in aged human alpha-synuclein transgenic mice.

  2006cited by this paper
• Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats

  2006cited by this paper
• Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice

  2006cited by this paper
• Loss of autophagy in the central nervous system causes neurodegeneration in mice

  2006cited by this paper
• Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys

  2006cited by this paper
• Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases?

  2006cited by this paper
• Diagnosis and treatment of Parkinson disease: molecules to medicine.

  2006cited by this paper
• Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease.

  2006cited by this paper
• Proteasome inhibition and Parkinson's disease modeling

  2006cited by this paper
• Lack of nigrostriatal pathology in a rat model of proteasome inhibition

  2006cited by this paper
• Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease.

  2006cited by this paper
• Identification of Far Upstream Element-binding Protein-1 as an Authentic Parkin Substrate*

  2006cited by this paper
• Proteasome inhibitor–induced model of Parkinson's disease

  2006cited by this paper
• Autophagy in neurons: it is not all about food.

  2006cited by this paper
• Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons

  2006cited by this paper
• Diverse Effects of Pathogenic Mutations of Parkin That Catalyze Multiple Monoubiquitylation in Vitro*

  2006cited by this paper
• Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.

  2006cited by this paper
• The proteasomal inhibition model of Parkinson's disease: “Boon or bust”?

  2006cited by this paper
• A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K–Akt signalling

  2006cited by this paper
• Proteasome dysfunction in aged human α-synuclein transgenic mice

  2006cited by this paper
• Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease

  2005cited by this paper
• Lithium induces autophagy by inhibiting inositol monophosphatase

  2005cited by this paper
• Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila.

  2005cited by this paper
• Ubiquitin-binding domains

  2005cited by this paper
• α-Synuclein and Parkin Contribute to the Assembly of Ubiquitin Lysine 63-linked Multiubiquitin Chains*

  2005cited by this paper
• Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up‐regulate iHSP70, following proteasomal inhibition

  2005cited by this paper
• Molecular pathogenesis of Parkinson's disease.

  2005cited by this paper
• Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation

  2005cited by this paper
• Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death

  2005influential reference
• Parkin-deficient mice are not a robust model of parkinsonism.

  2005cited by this paper
• Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.

  2005cited by this paper
• Proteasomal activity in brain differs between species and brain regions and changes with age.

  2005cited by this paper
• Geldanamycin Induces Heat Shock Protein 70 and Protects against MPTP-induced Dopaminergic Neurotoxicity in Mice*

  2005cited by this paper
• Parkin Gene Therapy for α-Synucleinopathy: A Rat Model of Parkinson's Disease

  2005cited by this paper
• Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function.

  2005cited by this paper
• Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: one for soluble Z variant of human alpha-1 proteinase inhibitor (A1PiZ) and another for aggregates of A1PiZ.

  2005cited by this paper
• Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila.

  2005cited by this paper
• Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition.

  2005cited by this paper
• Response to Comment on "S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function"

  2005cited by this paper
• Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

  2005cited by this paper
• Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease‐linked point mutations

  2005cited by this paper
• Autophagy in cell death: an innocent convict?

  2005cited by this paper
• Dopamine covalently modifies and functionally inactivates parkin

  2005cited by this paper
• Molecular pathogenesis of Parkinson's disease.

  2005cited by this paper
• Mechanisms of Suppression of α-Synuclein Neurotoxicity by Geldanamycin in Drosophila*

  2005cited by this paper
• Hsp70 Reduces α-Synuclein Aggregation and Toxicity*

  2004cited by this paper
• Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease

  2004cited by this paper
• parkin counteracts symptoms in a Drosophila model of Parkinson's disease

  2004cited by this paper
• S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function

  2004cited by this paper
• Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity.

  2004cited by this paper
• Decreased proteasome activity is associated with increased severity of liver pathology and oxidative stress in experimental alcoholic liver disease.

  2004cited by this paper
• Parkin attenuates manganese‐induced dopaminergic cell death

  2004cited by this paper
• Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

  2004cited by this paper
• Loss of locus coeruleus neurons and reduced startle in parkin null mice.

  2004cited by this paper
• Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity.

  2004cited by this paper
• Glucocorticoids regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S proteasome in fast-twitch skeletal muscles.

  2004cited by this paper
• Genetic causes of Parkinson’s disease: UCHL-1

  2004cited by this paper
• Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain.

  2004cited by this paper
• Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis.

  2004cited by this paper
• Proteasome Inhibition Alters Neural Mitochondrial Homeostasis and Mitochondria Turnover*

  2004cited by this paper
• Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

  2004cited by this paper
• Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.

  2004cited by this paper
• α-Synuclein Is Degraded by Both Autophagy and the Proteasome*

  2003cited by this paper
• A proteomics approach to understanding protein ubiquitination

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Characterization of chronic low‐level proteasome inhibition on neural homeostasis

  2003cited by this paper
• Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants

  2003cited by this paper
• Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function*

  2003cited by this paper
• The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates.

  2003cited by this paper
• Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function*

  2003cited by this paper
• α-Synuclein Locus Triplication Causes Parkinson's Disease

  2003cited by this paper
• Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila.

  2003influential reference
• Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons*

  2003influential reference
• alpha-Synuclein locus triplication causes Parkinson's disease.

  2003cited by this paper
• SEPT5_v2 is a parkin-binding protein.

  2003cited by this paper
• Altered proteasomal function in sporadic Parkinson's disease.

  2003influential reference
• Parkin Facilitates the Elimination of Expanded Polyglutamine Proteins and Leads to Preservation of Proteasome Function*

  2003cited by this paper
• Molecular Mechanisms of Neurodegeneration in Parkinson's Disease: Clues from Mendelian Syndromes

  2003cited by this paper
• Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse.

  2003cited by this paper
• RING finger 1 mutations in Parkin produce altered localization of the protein.

  2003cited by this paper
• Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age*

  2003cited by this paper
• Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity.

  2003cited by this paper
• Fine Structure and Biochemical Mechanisms Underlying Nigrostriatal Inclusions and Cell Death after Proteasome Inhibition

  2003cited by this paper
• Inactivation of Parkin by Oxidative Stress and C-terminal Truncations

  2003cited by this paper
• Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.

  2002cited by this paper
• Parkin Protects against the Toxicity Associated with Mutant α-Synuclein: Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons

  2002cited by this paper
• Lentiviral-Mediated RNA Interference

  2002cited by this paper
• Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons.

  2002cited by this paper
• Impairment of the ubiquitin‐proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures

  2002cited by this paper
• Brain proteasomal function in sporadic Parkinson's disease and related disorders

  2002cited by this paper

• From Bench to Brain: Translating EV and Nanocarrier Research into Parkinson’s Disease Therapies

  2025cites this paper
• Targeting CRABP1 Signalosomes in Managing Neurodegeneration

  2025cites this paper
• Computational analysis of transcriptome data and mapping of functional networks in Parkinson’s disease

  2025cites this paper
• Targeting Cdc42 improves motor phenotype in Parkinson’s disease mice and reveals age-dependent susceptibility to α-synuclein

  2025cites this paper
• Cinnarizine, a Calcium Channel Blocker, Partially Prevents the Striatal Dopamine Decline and Loss of Nigral Dopamine Neurons in the Lactacystin-Induced Rat Model of Parkinson’s Disease

  2025cites this paper
• Precision Enzyme: Targeted Drug Discovery in Neurodegenerative Disorders.

  2025cites this paper
• Parkin, a key player in Parkinson's disease pathogenesis: A review.

  2025cites this paper
• Boosting Brain Clean-Up: Can Targeting UPS Genes Offer Neuroprotection?

  2025cites this paper
• Therapeutic Potential of Sea Cucumber-Derived Bioactives in the Prevention and Management of Brain-Related Disorders: A Comprehensive Review

  2025cites this paper
• Oxidative Stress in Neurodegenerative Disorders: A Key Driver in Impairing Skeletal Muscle Health

  2025cites this paper
• Clearance Pathways for α‐Synuclein in Parkinson's Disease

  2025cites this paper
• Proteomic Analysis of Substantia Nigra Reveals Molecular Insights Into the Neuroprotection Effect of Rosmarinic Acid Treatment in MPTP‐Induced Mouse Model of Parkinson's Disease

  2025cites this paper
• Glycated α-Synuclein Renders Glial Cell Activation and Induces Degeneration of Dopaminergic Neurons: A Potential Implication for the Development of Parkinson's Disease.

  2025cites this paper
• Navigating the landscape of protein folding and proteostasis: from molecular chaperones to therapeutic innovations

  2025cites this paper
• Ubiquitin-proteasome pathway in disease

  2024cites this paper
• From the Gut to the Brain: Is Microbiota a New Paradigm in Parkinson’s Disease Treatment?

  2024cites this paper
• Hotspot site microenvironment in the deubiquitinase OTUB1 drives its stability and aggregation

  2024cites this paper
• Refining the clinical diagnosis of Parkinson's disease.

  2024cites this paper
• Modulation of the ubiquitin-proteasome system by curcumin: Therapeutic implications in cancer.

  2024cites this paper
• Pathophysiology of COVID-19-Related Extrapyramidal Disorders.

  2024cites this paper
• Chronic Cocaine Use and Parkinson’s Disease: An Interpretative Model

  2024cites this paper
• Unraveling neuroprotection in Parkinson’s disease: Nrf2–Keap1 pathway’s vital role amidst pathogenic pathways

  2024cites this paper
• NF-κB/c-Rel DNA-binding is reduced in substantia nigra and peripheral blood mononuclear cells of Parkinson's disease patients.

  2023cites this paper
• Systematic identification of structure-specific protein–protein interactions

  2023cites this paper
• Identification of Ubiquitination-Associated Proteins Using 2D-DIGE.

  2023cites this paper
• Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson’s disease

  2022cites this paper
• Dietary Plant Polyphenols as the Potential Drugs in Neurodegenerative Diseases: Current Evidence, Advances, and Opportunities

  2022influential citation
• Genetic Study of Early Onset Parkinson’s Disease in Cyprus

  2022cites this paper
• The disturbance of protein synthesis/degradation homeostasis is a common trait of age-related neurodegenerative disorders.

  2022cites this paper
• The ubiquitin–proteasome system and autophagy mutually interact in neurotoxin‐induced dopaminergic cell death models of Parkinson's disease

  2022cites this paper
• Ubiquitin-proteasome system in diabetic retinopathy

  2022cites this paper
• Deciphering Intertwined Molecular Pathways Underlying Metabolic Syndrome Leading to Parkinson's Disease.

  2022cites this paper
• Implications of intracellular protein degradation pathways in Parkinson's disease and therapeutics

  2022cites this paper
• Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease

  2022cites this paper
• A co‐expression network based molecular characterization of genes responsive for Braak stages in Parkinson's disease

  2022cites this paper
• Trophoblast glycoprotein is a new candidate gene for Parkinson’s disease

  2021cites this paper
• Prediction of neuro-degenerative disorders using sunflower optimisation algorithm and Kernel extreme learning machine: A case-study with Parkinson’s and Alzheimer’s disease

  2021cites this paper
• Trophoblast glycoprotein is a new candidate gene for Parkinson’s disease

  2021cites this paper
• Lack of Parkinsonian Pathology and Neurodegeneration in Mice After Long-Term Injections of a Proteasome Inhibitor in Olfactory Bulb and Amygdala

  2021cites this paper
• Synphilin-1 and its Effects on Pathogenesis of Parkinson’s Disease

  2021cites this paper
• Studying the effect of alpha-synuclein and Parkinson’s disease linked mutants on inter pathway connectivities

  2021cites this paper
• Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson’s disease biomarker panel

  2021cites this paper
• Highlighting the protective or degenerative role of AMPK activators in dementia experimental models.

  2021cites this paper
• Potential role of cannabidiol in Parkinson’s disease by targeting the WNT/β-catenin pathway, oxidative stress and inflammation

  2021cites this paper
• Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules

  2021cites this paper
• University of Southern Denmark Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson's Disease

  2021cites this paper
• Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway

  2021cites this paper
• Parkinson mice show functional and molecular changes in the gut long before motoric disease onset

  2020cites this paper
• Ensemble-based virtual screening in discovering potent inhibitors targeting Von Hippel-Lindau (VHL) E3 ubiquitin ligase.

  2020cites this paper
• Modulation of proteasome activity by curcumin and didemethylcurcumin

  2020cites this paper
• Does altering proteasomal activity and trafficking reduce the arborization mediated specific vulnerability of SNpc dopaminergic neurons of Parkinson's disease?

  2020cites this paper
• Functional and molecular early enteric biomarkers for Parkinson’s disease in mice and men

  2020cites this paper
• Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective

  2020cites this paper
• Alteration in the Expression of Parkinson’s-Related Genes in Rat Hippocampus by Exercise and Morphine Treatments

  2020cites this paper
• Clustering of Alzheimer’s and Parkinson’s disease based on genetic burden of shared molecular mechanisms

  2020cites this paper
• Circadian rhythms, Neuroinflammation and Oxidative Stress in the Story of Parkinson’s Disease

  2020cites this paper
• Potential treatment of Parkinson’s disease with omega-3 polyunsaturated fatty acids

  2020cites this paper
• Endothelin signalling in the retina

  2020cites this paper
• Freezing of gait in Parkinson’s disease: automatic early recognition of episodes from patients’ inertial data

  2020cites this paper
• A systems toxicology approach to compare the heavy metal mixtures (Pb, As, MeHg) impact in neurodegenerative diseases.

  2020cites this paper
• Neuronal Bmi-1 is critical for melatonin induced ubiquitination and proteasomal degradation of α-synuclein in experimental Parkinson's disease models.

  2020cites this paper
• Molecular evolutionary and structural analysis of human UCHL1 gene demonstrates the relevant role of intragenic epistasis in Parkinson’s disease and other neurological disorders

  2020cites this paper
• Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress

  2020cites this paper
• Immunotherapy for Parkinson’s disease

  2020cites this paper
• Underlying Mechanisms of Prolyl Oligopeptidase Inhibition, Deletion, and Restoration on the α-Synuclein Aggregation Process

  2019cites this paper
• Gene co-expression network analysis for identifying genetic markers in Parkinson's disease - a three-way comparative approach.

  2019cites this paper
• Proteomic Study of a Parkinson's Disease Model of Undifferentiated SH-SY5Y Cells Induced by a Proteasome Inhibitor

  2019cites this paper
• Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimer's disease, Parkinson's disease.

  2019cites this paper
• Parkinson’s Disease and Aging

  2019cites this paper
• Monitoring the Immunoproteasome in Live Cells Using an Activity-Based Peptide-Peptoid Hybrid Probe.

  2019cites this paper
• Biomarker Discovery with Mass Spectrometry Imaging and Profiling

  2019cites this paper
• Interneuronas estriatales productoras de GDNF: características moleculares y rol en la neuroprotección catecolaminérgica

  2019cites this paper
• Mitochondrial Proteins in the Development of Parkinson's Disease.

  2019cites this paper
• Validation of a novel progressive rat model of Parkinson’s disease using in vivo positron emission tomography, behavioural assessments, and in vitro autoradiography

  2019cites this paper
• Oxidative stress and neuroinflammation in the story of Parkinson’s disease: Could targeting these pathways write a good ending?

  2018cites this paper
• Caloric restriction rescues yeast cells from alpha-synuclein toxicity through autophagic control of proteostasis

  2018cites this paper
• Stem Cell Transplantation and Physical Exercise in Parkinson’s Disease, a Literature Review of Human and Animal Studies

  2018cites this paper
• The Triangle of Death in Alzheimer's Disease Brain: The Aberrant Cross-Talk Among Energy Metabolism, Mammalian Target of Rapamycin Signaling, and Protein Homeostasis Revealed by Redox Proteomics

  2017cites this paper
• Disease-Toxicant Interactions in Parkinson’s Disease Neuropathology

  2017cites this paper
• Small-molecule Modulation of HDAC6 Activity: The Propitious Therapeutic Strategy to Vanquish Neurodegenerative Disorders.

  2017cites this paper
• A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson’s disease

  2017cites this paper
• Alpha-synuclein and immune system crosstalk in parkinson's disease; therapeutic approaches of its modulation by molecular chaperones

  2017cites this paper
• Crystal structure of a low molecular weight activator Blm-pep with yeast 20S proteasome – insights into the enzyme activation mechanism

  2017cites this paper
• Proteomic studies associated with Parkinson’s disease

  2017cites this paper
• Gene expression profiling of midbrain dopamine neurons upon gestational nicotine exposure

  2016cites this paper
• Ion-catalyzed reactive oxygen species in sporadic models of parkinson’s disease

  2016cites this paper
• Aging-related diseases and autophagy

  2016cites this paper
• Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases.

  2016cites this paper
• It Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer Disease

  2016cites this paper
• Identification of Multiple QTLs Linked to Neuropathology in the Engrailed-1 Heterozygous Mouse Model of Parkinson’s Disease

  2016cites this paper
• Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson’s disease (PD)

  2016cites this paper
• Efficient and biologically relevant consensus strategy for Parkinson’s disease gene prioritization

  2016cites this paper
• The interplay between alpha-synuclein and ATP13A2 : towards the understanding of the molecular basis of Parkinson’s disease

  2016cites this paper
• Regulation of Parkin by R 1 and UBL domains 1 Interaction between RING 1 ( R 1 ) and Ubiquitin-Like ( UBL ) Domain Is Critical for the Regulation of Parkin Activity

  2015cites this paper
• Methylmercury can induce Parkinson's-like neurotoxicity similar to 1-methyl-4- phenylpyridinium: a genomic and proteomic analysis on MN9D dopaminergic neuron cells.

  2015cites this paper
• Modulation of the expression and function of dopaminergic presynaptic proteins by the statins : Potential implication for the therapeutic intervention in Parkinson’s disease.

  2015cites this paper
• (Poly)phenols protect from α-synuclein toxicity by reducing oxidative stress and promoting autophagy.

  2015cites this paper
• Understanding the intracellular regulation of interleukin-1

  2015cites this paper
• Interaction between RING1 (R1) and the Ubiquitin-like (UBL) Domains Is Critical for the Regulation of Parkin Activity*

  2015cites this paper
• Polyphenols neuroprotective effect in a Parkinson’s disease yeast model: phosphoproteome alterations

  2015cites this paper